Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Pfizer and BioNTech Announce Phase -2-

10/21/2021 | 06:46am EST

Individuals should tell the vaccination provider about all of their medical conditions, including if they:

   -- have any allergies 
 
   -- have had myocarditis (inflammation of the heart muscle) or pericarditis 
      (inflammation of the lining outside the heart) 
 
   -- have a fever 
 
   -- have a bleeding disorder or are on a blood thinner 
 
   -- are immunocompromised or are on a medicine that affects the immune system 
 
   -- are pregnant, plan to become pregnant, or are breastfeeding 
 
   -- have received another COVID-19 vaccine 
 
   -- have ever fainted in association with an injection 

The vaccine may not protect everyone.

Side effects reported with the vaccine include:

   -- There is a remote chance that the vaccine could cause a severe allergic 
      reaction-- A severe allergic reaction would usually occur within a few 
      minutes to one hour after getting a dose of the vaccine. For this reason, 
      vaccination providers may ask individuals to stay at the place where they 
      received the vaccine for monitoring after vaccination 
 
   -- Signs of a severe allergic reaction can include difficulty breathing, 
      swelling of the face and throat, a fast heartbeat, a bad rash all over 
      the body, dizziness, and weakness 
 
   -- If an individual experiences a severe allergic reaction, they should call 
      9-1-1 or go to the nearest hospital 
 
   -- Myocarditis (inflammation of the heart muscle) and pericarditis 
      (inflammation of the lining outside the heart) have occurred in some 
      people who have received the vaccine. In most of these people, symptoms 
      began within a few days following receipt of the second dose of the 
      vaccine. The chance of having this occur is very low. Individuals should 
      seek medical attention right away if they have any of the following 
      symptoms after receiving the vaccine: 
 
          -- chest pain 
 
          -- shortness of breath 
 
          -- feelings of having a fast-beating, fluttering, or pounding heart 
 
   -- Side effects that have been reported with the vaccine include: 
 
          -- severe allergic reactions; non-severe allergic reactions such as 
             rash, itching, hives, or swelling of the face; myocarditis 
             (inflammation of the heart muscle); pericarditis (inflammation of 
             the lining outside the heart); injection site pain; tiredness; 
             headache; muscle pain; chills; joint pain; fever; injection site 
             swelling; injection site redness; nausea; feeling unwell; swollen 
             lymph nodes (lymphadenopathy); decreased appetite, diarrhea; 
             vomiting; arm pain fainting in association with injection of the 
             vaccine 
 
   -- These may not be all the possible side effects of the vaccine. Serious 
      and unexpected side effects may occur. The possible side effects of the 
      vaccine are still being studied in clinical trials. Call the vaccination 
      provider or your healthcare provider if you have any side effects that 
      bother you or do not go away 

Data on administration of this vaccine at the same time as other vaccines has not yet been submitted to FDA. Individuals considering receiving this vaccine with other vaccines, should discuss their options with their healthcare provider.

Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1--800--822--7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.

Please https://www.globenewswire.com/Tracker?data=y6_vrNVlhT-CnXiIl2DrEF_H-9dgcdOSTIgRJHM3u9URa9-JSxEYkT7v40TzMOjsAhIpRyJ_akrXw4wzWYjgKYtgkDX7mjW2Ex7jCvuSFurVdXoaEALSEgBQULMt5dz9RCByhThF7KI8N3S8YAel3-NGyzL8SmIzZUh1p-kR4VCuiXciZ8OvtDGnXswPID3lRWtjFXVddKKtoWliLQxwUV-szmIMorqfvH_--MD02YbC0oKFOfiXeONmPrllrawYrB7c2uF50PR4y5ZUdaWlOB6gsGrZgaGhLGnO0D0u7vBebjitxe-VfPnOJhUjCxUuYyhIdx1bTwzDlCDqN-WbQHs_CVJcfI9h-5rt46ST9Zc= click here for full Prescribing Information (16+ years of age). Please https://www.globenewswire.com/Tracker?data=y6_vrNVlhT-CnXiIl2DrEKtjtTkBuFf69rq-6wqEGTKZ5tibs9OxVwmZgpzm1Fnib8OUTAd7_n3dU2g_UJAX-jehDBK_HG02AwTM1DabSUJFiuqF_Cm1iwZbPdrI736kwHl3TnMXbU13Z3qRdNF5XQ== click here for Fact Sheet for Vaccination Providers (12+ years of age). Please https://www.globenewswire.com/Tracker?data=y6_vrNVlhT-CnXiIl2DrEFenCf0EkKD9in8Z0d3knMPtyvhc19DbcsCeRj7bWIKoyqs2XKmBS_3TD_yOnDk57X26YkO4RRlGUiLP4GSCEcD64DfUQK7FfGwMyGL0MccA4yhcXA7RtwLdbRPmOUmJwA== click here for the Recipients and Caregivers Fact Sheet.

About Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at https://www.globenewswire.com/Tracker?data=5JaDr_uZVG8dk0OQV0B6UarLEzI7ARB2Hd-EHxPR0kOK-Cw8dX78hY4LXu27PMZeofO2_x3jz9MTn9Y9eOX4zMBF75vLKvuDwPkp1_fyLn6K3dRzsHJEQzjpXjImwzChPZ9wVa1U352djI8j4Okv-ldzAoNwLGd76U94OaRX9PF_s7cAy4pzxVhESVFBTkq564qgjAml9F5cLauENuVbhNIku77rO545M0xi1thbXlFUzgqzTXhqFDzrG60smTdGgFWgJzeagSkB3h7VvvgaJf2HeIFczHDt_M-J7KhTRis= www.Pfizer.com. In addition, to learn more, please visit us on https://www.globenewswire.com/Tracker?data=5JaDr_uZVG8dk0OQV0B6URcoWG4TakJbzKuNHQcG08F4LkZVmlBaGF6vRWGY3pjLfZ3ARrhMCbUBdJBd6QK2_wtSX0yXNp5RBqi56zm9GSMgCMsRm4IToMy5DLw7C_fvSWo4e3l8cGNe_-dG6CiPci-efi0wHJZONx2qE6FsgtG0WbVMvOjYLA4Zl8TmqcXvtOqUC_VWxt4n7ydNrOLRI51RJ9MqlQOF3cqaHZT4eXEUv7x6l8YBQNPvlUFBbucnGAr0aZB_BMn0bkL9IKFJIE0yrlqcc-OwczePffxKgxA= www.Pfizer.com and follow us on Twitter at https://www.globenewswire.com/Tracker?data=PAQl7mEcwwvSv_fWOX02kqzhkNYVgcbNaHtrvbhywYQ_UyaP2c4R_WbUWho4eXtimp9V3i4l5v5EXY7rsVDGhoM2hFhq1oU9fI3knAGOnigKiZoLWo1R2KwTDBOdXWqpa8NeKIl3UMXqSK9JQi4BzEM7tOH9dbf1gI_TJwNe_UOdMwSrcG_J7wDI41ZDYwlobmcehTUHl40EfISPMf1YjBFfulR3uXAtw_xH6y-D7eEcAsbjdjy0hjVoS67F3UmBLnEPvyGxbTAfqjH39F3PLg== @Pfizer and https://www.globenewswire.com/Tracker?data=PAQl7mEcwwvSv_fWOX02kh8pf1EPQt1wxK_IldMqzuihzEmzCRWMbYWj1ZO3ivaBoBUIkpvJuafeM0CeOOaGYnLQfbNW0hr8LwVjsFvx_LvMqAvgCXqzqW9A5RtlU-K0SUiCMdu2eyqP4xqnbifpBKwdzxMG1TwiXuBB_7KToVldJe2YWBbPHlho1HPV_Otwyqh8-JiN2s9sLpwfMTHuuI0ZvBLoQ0w7XtTsb2tpWNbwHT6-oZ2ij-nrdE7MBjVga1H13eZezw4se5sYNuOh-gXZGbOAp84Ah5ITqU4P35s= @Pfizer News, https://www.globenewswire.com/Tracker?data=E9GmkGhkHlAbKZKBpW1jB7qHQ79MSdtgJexYNPWxDazLf_99s8LLIiLGe1ktzvXGn3KYu0cAzCn5bUN4au3KZ23tIQjeR0fyN7g64XEp8aKWT2vVj5cqw4G9Sq4X_6Hchke5Wi-d8ndUZNl2iu9lJKxwHgbyxuLzj5rLYyhctj16Q_ec3Ob1Zj4FmDmYFoO77ItLdA7seqjjs1IliCn7V-ddFQbaZAZAOU6Wc51ixWxZIdw7iycCEroFl2FhXyq8tBvjt3-gNrW3L_NeLmt4SVrcN4xlME4CtbL8WTcFz3I= LinkedIn, https://www.globenewswire.com/Tracker?data=HPrPnaNEZwpju6iDYmNg3LdqYj-K7VoD1zWiJt2W0YpyyGpSh7Vt2v_ivlhsk4Flx18bWcmf4Duq7-Pmfx-I-xzGM3HwLUet5Ya69gkd7F7YpimrXmSstf2b1G5vfkYi0ICQGKYea42Hl7VxKsM2LkiDOK0Cng_CaQ4JL26Z7AocWbLemybm0ubQ3fHaqW8krTgh2xXaQpAT5LGWNvxBSPggp80vDgH8KoRrHJR6VrHtzXnY60lz7It9Px6ngTcNFUDiacoPrW_CJTax__uOgMFQC_yrrINjPmbjm5Fh33Q= YouTube and like us on Facebook at https://www.globenewswire.com/Tracker?data=GQrA1Wywp81hzpma44E0t4qYz_g75a4b0MyvlkSuQF5HRnWpAiWfwdB95fg3cs6EyWWfWamRQk7cgNgryUTcnY8OIhtpDJ-iJzxuoyBXT-m52RVeusXcGfBuE4qQd1z6k9zEI2q-aqHpAW4w-ee-bSvhFsS12bzvrBCO0TImee78uFw8iuvIu4j3d-ZDj9AGKvSCPfboIG7WLqMXejfuAhXApCqN1kvQ__vkFM0Jo21Ya4A4kwuC_k62fjCfY9Iho73fQqadW2deD3B9kWj6kFdXdu5dDwPL1P_MLs1zR0zmYe2cEScUOhpxaZRU3aM3 Facebook.com/Pfizer.

Pfizer Disclosure Notice

The information contained in this release is as of October 21, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer's efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including potential of booster doses, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of data readouts, regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse

(MORE TO FOLLOW) Dow Jones Newswires

October 21, 2021 06:45 ET (10:45 GMT)

All news about BIONTECH SE
03:58pStocks Slide From Earlier Gains Wednesday as US Confirms First Case of Omicron Variant
MT
01:33pEquities Led Higher Midday by Energy, Financials Following BioNTech CEO Comment on Vacc..
MT
01:24pMIDDAY REPORT : US Stocks Led Higher by Energy, Financials Following BionTech CEO Comment ..
MT
12:50pCuba to upgrade homegrown COVID-19 vaccine to confront Omicron
RE
12:43pMIDDAY ETF UPDATE : Broad-Market ETFs Higher; US Stocks Led Higher by Energy, Financials i..
MT
12:33pUS Stocks Led Higher by Energy, Financials in Midday Trading
MT
12:08pGLOBAL MARKETS LIVE : Merck, Volkswagen, Salesforce, Roche, Mondelez...
11:10aWALL STREET STOCK EXCHANGE : The Fed takes a new stance
11:08aEuropean ADRs Move Sharply Higher in Wednesday Trading
MT
06:50aEU To Start Early COVID-19 Vaccinations For Children Aged Five To 11
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 17 474 M 19 777 M 19 777 M
Net income 2021 9 220 M 10 435 M 10 435 M
Net cash 2021 9 793 M 11 084 M 11 084 M
P/E ratio 2021 8,45x
Yield 2021 -
Capitalization 74 976 M 84 953 M 84 857 M
EV / Sales 2021 3,73x
EV / Sales 2022 3,23x
Nbr of Employees 2 800
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 310,43 €
Average target price 260,16 €
Spread / Average Target -16,2%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Sierk P÷tting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE331.48%84 953
GILEAD SCIENCES, INC.18.31%86 465
WUXI APPTEC CO., LTD.30.33%66 734
REGENERON PHARMACEUTICALS31.76%66 553
VERTEX PHARMACEUTICALS-20.90%47 530
BEIGENE, LTD.34.50%32 613